

ABSTRACT

A pharmaceutical composition for treating and preventing diseases, disorders and/or conditions of airway inflammation, airway stenosis or nasal cavity inflammation caused by the expression of a gene regulated by NF-kappaB which contains an NF-kappaB decoy and a pharmaceutically acceptable carrier. The above diseases may be asthma, COPD or rhinitis. Moreover, the above diseases may be diseases caused by an eosinophil abnormality (for example, asthma, rhinitis and COPD). The pharmaceutically acceptable carrier may be a hydrophilic polymer, a liposome and so on.